GlassScriptPhysician profile
Catherine Masry Marcucci
NPI 1174801278
$5,578.03
in general payments reported to CMS, 2019-2025
38 companies · $3,867 in 2025
The $3,867 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $166 · 2024: $1,545 · 2025: $3,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,045 · Consulting Fee: $1,395 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,044.54 |
| Consulting Fee | $1,395.00 |
| Education | $138.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $1,449.73 | 2024-2025 | Epkinly |
| Abbvie INC. | $414.79 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $322.65 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $314.74 | 2024-2025 | Calquence |
| Syndax Pharmaceuticals, INC. | $255.08 | 2025 | Revuforj |
| Adc Therapeutics America, INC. | $248.20 | 2024-2025 | |
| Beigene USA, INC. | $189.71 | 2024 | Brukinsa |
| Cardinal Health 110 LLC | $175.00 | 2025 | |
| Pfizer INC. | $169.65 | 2023-2025 | |
| Janssen Biotech, INC. | $168.76 | 2024 | Darzalex, Tecvayli, Talvey |
| Genzyme Corporation | $138.52 | 2024-2025 | |
| Astellas Pharma US INC | $125.78 | 2025 | Vyloy |
| Genentech USA, INC. | $124.41 | 2023-2025 | Venclexta, Polivy, Tecentriq |
| Celgene Corporation | $123.51 | 2024-2025 | Breyanzi, Pomalyst, Reblozyl |
| Legend Biotech USA INC. | $105.12 | 2025 | Carvykti |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $99.95 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Servier Pharmaceuticals LLC | $99.09 | 2024-2025 | |
| Seagen INC. | $92.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.89 | 2024-2025 | Iclusig, Ninlaro |
| Taiho Oncology, INC. | $82.15 | 2023-2025 | |
| Sobi, INC | $79.54 | 2025 | |
| Incyte Corporation | $78.92 | 2024-2025 | Monjuvi |
| Lilly USA, LLC | $77.52 | 2023-2025 | Jaypirca, Retevmo, Verzenio |
| Agios Pharmaceuticals, INC. | $66.17 | 2025 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $62.32 | 2024-2025 | Onivyde, Tazverik |
| Blueprint Medicines Corporation | $57.24 | 2024-2025 | Ayvakit |
| Glaxosmithkline, LLC. | $48.05 | 2024-2025 | Ojjaara |
| Beone Medicines USA, INC. | $44.13 | 2025 | Brukinsa |
| Cycle Pharmaceuticals INC | $42.09 | 2025 | Phyrago |
| Karyopharm Therapeutics INC. | $39.74 | 2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $31.55 | 2024 | |
| Merck Sharp & Dohme LLC | $30.11 | 2024 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $28.87 | 2023 | Libtayo |
| Stemline Therapeutics INC. | $24.20 | 2025 | Elzonris |
| Alexion Pharmaceuticals, INC. | $24.17 | 2024 | Ultomiris |
| Pharmaessentia USA Corporation | $22.78 | 2024 | Besremi |
| Azurity Pharmaceuticals, INC. | $19.59 | 2025 | Danziten |
| Acrotech Biopharma INC. | $18.32 | 2025 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Marcucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.